New Protein Discovery May Transform Pancreatic Cancer Care

Scientists just found a way to help the immune system see and fight one of the deadliest cancers.

Researchers at The University of Texas MD Anderson Cancer Center identified a protein called DPY30 that acts like a protective shield for pancreatic cancer cells. When they blocked this protein in lab studies, previously "cold" tumors that ignored immunotherapy suddenly became "hot" and responsive to treatment.

The discovery centers on how cancer cells copy their DNA. DPY30 helps stabilize stressed replication forks, the critical sites where DNA strands separate and copy themselves during cell division. This stabilization keeps cancer cells alive even when they're damaged and under stress.

When researchers removed DPY30 from pancreatic cancer cells, something remarkable happened. The unstable DNA triggered inflammatory signals that attracted immune cells into the tumor. Suddenly, the immune system could recognize and attack cancer that had been invisible before.

Dr. Francesca Citron, who led the study published in Cancer Research, explained that understanding DPY30's role could tremendously impact future treatment strategies. The protein works as an epigenetic switch, meaning it controls how genes function without changing the DNA itself.

The Bright Side

This discovery offers hope on two fronts. First, DPY30 levels in patient tumors could predict who will respond best to immunotherapy, helping doctors personalize treatment plans. Patients with higher DPY30 levels currently face poorer outcomes, but knowing this information upfront means doctors can adjust strategies accordingly.

Second, combining DPY30 inhibitors with immunotherapy could create powerful new treatment combinations. Instead of just using immunotherapy alone, which often fails against pancreatic cancer, doctors might one day block DPY30 first to wake up the immune system, then follow with immunotherapy to attack the newly visible tumor.

Pancreatic cancer desperately needs better options. It remains one of the most challenging cancers to treat, with limited effective therapies available to patients. The research team received support from multiple organizations including the Cancer Prevention and Research Institute of Texas and the National Institutes of Health.

The study revealed that DPY30 plays a completely different role in cancer than scientists previously understood. Beyond its known function in controlling which genes turn on or off, it specifically protects stressed replication forks in cancer cells.

Clinical trials haven't started yet, but the research provides a clear path forward. Scientists now know what to target, how it works, and which patients might benefit most.

This breakthrough transforms our understanding of how pancreatic tumors evade the immune system and gives researchers a concrete target for developing new combination therapies that could finally give patients the effective treatments they deserve.